Leslie Evell Sharp

US Patent:

20230025706, Jan 26, 2023

Filed:

Aug 22, 2022

Appl. No.:

17/893052

Inventors:

- Phoenix AZ, US
- Scottsdale AZ, US
Nancy VILLA - Tempe AZ, US
Lino TORRES-DOMINGUEZ - Tempe AZ, US
Lina FRANCO ACHURY - Tempe AZ, US
Leslie Lynne SHARP - Rancho Santa Fe CA, US

International Classification:

C07K 14/005
A61K 39/275
A61P 35/04
A61K 45/06
C07K 14/54
C07K 14/525
C12N 7/00
A61K 39/00

Abstract:

Disclosed herein, in certain embodiments, are recombinant myxoma viruses (MYXVs) and nucleic acid constructs encoding the recombinant MYXVs. In some embodiments, the MYXVs are engineered to inactivate or attenuate an activity or expression level of an M153 protein. In some embodiments, the MYXVs are engineered to express one or more transgenes such as a tumor necrosis factor (TNF), interleukin-12 (IL-12), or decorin. Also disclosed herein, in certain embodiments, are methods of using the MYXVs. Some embodiments include providing a MYXV as described herein to a subject in need thereof.

US Patent:

20210324014, Oct 21, 2021

Filed:

Jun 24, 2021

Appl. No.:

17/357624

Inventors:

- Scottsdale AZ, US
- Phoenix AZ, US
Nancy VILLA - Tempe AZ, US
Lino TORRES-DOMINGUEZ - Tempe AZ, US
Lina FRANCO ACHURY - Tempe AZ, US
Leslie Lynne SHARP - Rancho Santa Fe CA, US

International Classification:

C07K 14/005
C07K 14/525
C07K 14/54
A61P 35/04
A61K 45/06
A61K 39/275
C12N 7/00

Abstract:

Disclosed herein, in certain embodiments, are recombinant myxoma viruses (MYXVs) and nucleic acid constructs encoding the recombinant MYXVs. In some embodiments, the MYXVs are engineered to inactivate or attenuate an activity or expression level of an M153 protein. In some embodiments, the MYXVs are engineered to express one or more transgenes such as a tumor necrosis factor (TNF), interleukin-12 (IL-12), or decorin. Also disclosed herein, in certain embodiments, are methods of using the MYXVs. Some embodiments include providing a MYXV as described herein to a subject in need thereof.

US Patent:

20210061864, Mar 4, 2021

Filed:

Sep 2, 2020

Appl. No.:

17/010711

Inventors:

- Scottsdale AZ, US
- Phoenix AZ, US
Nancy VILLA - Tempe AZ, US
Lino TORRES-DOMINGUEZ - Tempe AZ, US
Lina FRANCO ACHURY - Tempe AZ, US
Leslie Lynne SHARP - Rancho Santa Fe CA, US

International Classification:

C07K 14/005
C12N 7/00
C07K 14/525
C07K 14/54
A61P 35/04
A61K 45/06
A61K 39/275

Abstract:

Disclosed herein, in certain embodiments, are recombinant myxoma viruses (MYXVs) and nucleic acid constructs encoding the recombinant MYXVs. In some embodiments, the MYXVs are engineered to inactivate or attenuate an activity or expression level of an M153 protein. In some embodiments, the MYXVs are engineered to express one or more transgenes such as a tumor necrosis factor (TNF), interleukin-12 (IL-12), or decorin. Also disclosed herein, in certain embodiments, are methods of using the MYXVs. Some embodiments include providing a MYXV as described herein to a subject in need thereof.